Study Name: Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrex
13 locations found
- GSK Investigational Site
Location: Albany, New York 12206
- GSK Investigational Site
Location: Norfolk, Virginia 23502
- GSK Investigational Site
Location: Greenville, South Carolina 29605
- GSK Investigational Site
Location: Nashville, Tennessee 37203
- GSK Investigational Site
Location: Dallas, Texas 75246
- GSK Investigational Site
Location: Tyler, Texas 75702
- GSK Investigational Site
Location: Houston, Texas 77030
- GSK Investigational Site
Location: Denver, Colorado 80218
- GSK Investigational Site
Location: Scottsdale, Arizona 85259
- GSK Investigational Site
Location: Las Vegas, Nevada 89169
- GSK Investigational Site
Location: Duarte, California 91010
- GSK Investigational Site
Location: Sacramento, California 95817
- GSK Investigational Site
Location: Vancouver, Washington 98684
|